What is new, and what is not
Science Group's (LSE:SAG) announcements in the past fortnight have been administrative. On 16 November 2026 it reported buying 52,000 shares between 9 and 12 November at about £5.67 to £5.68 each, leaving 40,035,593 shares in issue outside treasury and 6,150,281 in treasury. On 9 November it published a notification showing Artemis Investment Management had crossed the 5% threshold on 5 November, holding 2,099,116 voting rights, or 5.23%.
Neither filing alone changes the underlying trading picture. The most recent trading information remains the interim results for the six months to 30 June 2026, published on 27 July. This piece examines a theme from those results that tends to receive less attention: the deliberate shrinking of low-margin defence Revenue and what that implies for the second half.
Smaller revenue, wider margin
Total first-half revenue fell to £47.2m from £57.2m, but core revenue, which strips out pass-through defence work, eased only to £46.4m from £48.7m. Adjusted operating profit edged up to £11.5m from £11.3m, lifting the adjusted Margin to 24.3% from 19.7%. Adjusted Basic Earnings Per Share rose to 20.4p from 19.3p, helped by a lower share count. Statutory profit before tax was £8.1m, against £32.2m in 2025, when a £24.0m gain on a corporate investment inflated the comparison.
The company (LSE:SAG) said the gap between the two revenue measures reflects a managed run-down of pass-through activity inherited with TP Group, acquired in 2023. In the Sagentia services division, pass-through revenue was £0.8m against £4.2m a year earlier. At CMS2, the Portsmouth submarine atmosphere systems business, £4.3m of low-margin consumables revenue in the first half of 2025 did not recur.
Defence timing and a lumpy margin
Management said the completion of that transition coincided with delays to the UK Defence Investment Plan, which disrupted contracting across the sector. With the plan released in July 2026, it said Sagentia Defence was already seeing improvement and expected that to continue. Services adjusted operating profit was £7.0m (H1 2025: £7.9m) at a 24.0% margin, also affected by Middle East tensions slowing client decisions.
CMS2 reported an unusually high 38.3% margin and £4.3m of adjusted operating profit, which the company attributed to contract timing. It said that this business's revenue and margins vary considerably and that a more normal margin is expected for 2026 as a whole. Frontier, the radio and audio module business, was broadly flat at £6.8m revenue and £0.9m profit despite higher memory chip costs.
Why it matters
The group has traded revenue for quality: less turnover, but a larger share converting to profit. The board said it anticipates sequential growth in the second half, driven mainly by services. Cash conversion was 94%, group cash was £67.9m with net funds of £56.8m at 30 June, and a £30.0m revolving Facility was undrawn, leaving room for acquisitions alongside a buyback the board expected to exceed £20.0m in 2026.
Factors to watch
The second-half recovery depends partly on UK defence procurement, which Science Group (LSE:SAG) does not control, and on corporate clients regaining confidence. A normalising CMS2 margin will act as a drag on group profitability compared with the first half. Interim figures are unaudited, and no update on trading has been issued since July. Group cash had fallen from £82.0m a year earlier, after £26.3m was returned to shareholders over twelve months and £5.1m of tax was paid on the 2025 investment gain. The Artemis filing shows a holding, not an intention.
What to watch
The financial year ends on 31 December 2026. The company has not announced a date for its next trading update or full-year results, so investors will rely on weekly buyback notices until then. The key test will be whether services profit recovers enough to offset any CMS2 margin normalisation.

_11_17_2026_13_00_51_895454.jpg)




Please wait processing your request...